
HEXO Corp. HEXO
Annual report 2022
added 12-23-2023
HEXO Corp. Operating Cash Flow 2011-2026 | HEXO
Annual Operating Cash Flow HEXO Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -43.1 M | -94.6 M | -125 M | -22.2 M | - | - | - | - | - | - | - |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -22.2 M | -125 M | -71.1 M |
Operating Cash Flow of other stocks in the Drug manufacturers industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
-14.3 M | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
-166 M | $ 1.19 | - | $ 128 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
-12.7 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
-34.4 M | - | - | $ 50.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-462 M | - | -0.1 % | $ 2.03 B | ||
|
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-4.98 M | - | - | $ 36.6 M | ||
|
Emergent BioSolutions
EBS
|
-206 M | $ 13.9 | - | $ 712 M | ||
|
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | $ 21.5 | - | $ 2.05 B | ||
|
Evolus
EOLS
|
-18 M | $ 5.66 | - | $ 351 M | ||
|
Harrow Health
HROW
|
3.84 M | $ 51.0 | -4.67 % | $ 1.66 B | ||
|
China Pharma Holdings
CPHI
|
-466 K | $ 1.35 | 5.88 % | $ 23.6 M | ||
|
Sundial Growers
SNDL
|
-155 M | $ 1.65 | - | $ 3.37 M | ||
|
Jupiter Wellness
JUPW
|
-7.57 M | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
-28.6 M | $ 1.68 | - | $ 402 M | ||
|
Bausch Health Companies
BHC
|
1.03 B | $ 7.9 | 3.47 % | $ 2.88 B | ||
|
Pacira BioSciences
PCRX
|
189 M | $ 26.0 | - | $ 1.2 B | ||
|
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-612 K | $ 5.19 | - | $ 73 M | ||
|
Neoleukin Therapeutics
NLTX
|
-51.4 M | - | - | $ 193 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 3.74 | -1.58 % | $ 4.64 M | ||
|
Organogenesis Holdings
ORGO
|
14.2 M | $ 4.3 | - | $ 566 M | ||
|
Aurora Cannabis
ACB
|
-211 M | $ 4.24 | - | $ 86.3 M | ||
|
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | ||
|
Veru
VERU
|
-21.7 M | $ 2.37 | 1.72 % | $ 320 M | ||
|
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | ||
|
Perrigo Company plc
PRGO
|
363 M | $ 14.59 | -1.19 % | $ 2 B | ||
|
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | ||
|
Rockwell Medical
RMTI
|
-9.41 M | $ 0.95 | 2.78 % | $ 22.2 M | ||
|
cbdMD
YCBD
|
-353 K | $ 1.1 | - | $ 4.74 M | ||
|
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | ||
|
Relmada Therapeutics
RLMD
|
-51.7 M | $ 4.32 | 5.88 % | $ 130 M | ||
|
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
49.6 M | $ 9.43 | -1.05 % | $ 670 M | ||
|
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
-100 M | $ 5.61 | - | $ 229 M | ||
|
SCYNEXIS
SCYX
|
60.2 M | $ 0.64 | - | $ 30.6 M | ||
|
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
7.91 M | $ 8.99 | - | $ 5.56 B | ||
|
TherapeuticsMD
TXMD
|
-159 M | $ 2.04 | - | $ 21.3 M | ||
|
Viatris
VTRS
|
3 B | $ 12.46 | - | $ 15.1 B | ||
|
Zomedica Corp.
ZOM
|
-16 M | - | -0.21 % | $ 98 M |